LAKE FOREST, Ill., Oct. 21 /PRNewswire-FirstCall/ -- Hospira, Inc.
(NYSE: HSP), the world leader in generic injectable
pharmaceuticals, today announced the launch of piperacillin and
tazobactam for injection in the United
States. The medication is a generic version of Zosyn®, the
world's leading injectable antibiotic, from Pfizer (Wyeth).
Piperacillin and tazobactam injection posted 2009 U.S. sales of
more than $855 million.
Piperacillin and tazobactam for injection is a broad-spectrum
antibiotic used to treat patients with moderate to severe
infections. It is an injectable combination product that consists
of piperacillin (an extended-spectrum penicillin) and tazobactam (a
beta-lactamase inhibitor).
"The launch of piperacillin and tazobactam for injection
represents another significant generic injectable introduction for
Hospira this year, furthering our goal of taking costs out of the
healthcare system by providing high-quality, lower-cost
alternatives to proprietary medications," said Joshua Gordon, vice president, Specialty
Pharmaceuticals, Hospira.
Hospira's piperacillin and tazobactam product portfolio extends
beyond the formulations available from the originator. In addition
to immediately offering the injectable medication in 2.25 g, 3.375
g and 4.5 g single-dose vials, Hospira will also market the only
piperacillin and tazobactam for injection in Hospira's proprietary
ADD-Vantage™ system.
The ADD-Vantage ready-to-use drug delivery system from Hospira
enhances customer convenience and aids patient safety by
eliminating the need for needles. To help hospitals reduce
medication errors, Hospira also labels all of its injectable
products with unit-of-use bar codes.
Hospira currently markets the piperacillin and tazobactam
combination injectables in more than a dozen markets outside
the United States, with plans to
expand the launch to several Asian markets in late 2010 and early
2011.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™. As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake
Forest, Ill., and has approximately 13,500 employees. Learn
more at www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the growth opportunities for
certain generic specialty injectable products. Hospira cautions
that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Economic,
competitive, governmental, regulatory, legal, technological and
other factors that may affect Hospira's operations and may cause
actual results to be materially different from expectations include
the risks, uncertainties and factors discussed under the headings
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in Hospira's latest
Annual Report on Form 10-K and subsequent Forms 10-Q filed with the
Securities and Exchange Commission, which are incorporated by
reference. Hospira undertakes no obligation to release publicly any
revisions to forward-looking statements as the result of subsequent
events or developments.
SOURCE Hospira, Inc.
Copyright . 21 PR Newswire